for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aldeyra Therapeutics Inc

ALDX.OQ

Latest Trade

11.92USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

3.95

 - 

15.95

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
11.92
Open
--
Volume
--
3M AVG Volume
48.27
Today's High
--
Today's Low
--
52 Week High
15.95
52 Week Low
3.95
Shares Out (MIL)
57.63
Market Cap (MIL)
686.96
Forward P/E
-11.87
Dividend (Yield %)
--

Next Event

Q2 2021 Aldeyra Therapeutics Inc Earnings Release

Latest Developments

More

Aldeyra Therapeutics Reports Q1 Loss Per Share $0.25

Aldeyra Therapeutics Announces Pricing Of $125 Mln Public Offering Of Common Stock

Aldeyra Therapeutics Announces Proposed $125 Mln Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.

Industry

Biotechnology & Drugs

Contact Info

131 Hartwell Ave Ste 320

LEXINGTON, MA

02421-3105

United States

+1.781.7614904

https://www.aldeyra.com/

Executive Leadership

Richard H. Douglas

Independent Chairman of the Board

Todd C. Brady

President, Chief Executive Officer, Director

Joshua Reed

Chief Financial Officer

Stephen Machatha

Chief Development Officer

Ben R. Bronstein

Independent Director

Key Stats

1.55 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-1.790

2019

-2.240

2020

-1.110

2021(E)

-1.004
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
4.51
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
12.08
LT Debt To Equity (MRQ)
8.04
Return on Investment (TTM)
-40.11
Return on Equity (TTM)
-37.06

Latest News

Latest News

BRIEF-Aldeyra Therapeutics Announces New Drug Application Development Plans For Dry Eye Disease

* ALDEYRA THERAPEUTICS ANNOUNCES NEW DRUG APPLICATION (NDA) DEVELOPMENT PLANS FOR DRY EYE DISEASE

BRIEF-Aldeyra Receives Orphan Medicinal Product Designation From European Commission For ADX-2191 Retinal Disease Program

* ALDEYRA THERAPEUTICS RECEIVES ORPHAN MEDICINAL PRODUCT DESIGNATION FROM EUROPEAN COMMISSION FOR ADX-2191 RETINAL DISEASE PROGRAM Source text for Eikon: Further company coverage:

BRIEF-Aldeyra Therapeutics Reaches Agreement With FDA To Use RASP as An Objective Sign For The Treatment Of Dry Eye Disease

* ALDEYRA THERAPEUTICS REACHES AGREEMENT WITH THE US FOOD AND DRUG ADMINISTRATION FOR THE USE OF RASP AS AN OBJECTIVE SIGN FOR THE TREATMENT OF DRY EYE DISEASE

BRIEF-Aldeyra Therapeutics To Test ADX-1612 Against COVID-19

* ALDEYRA THERAPEUTICS TO ADVANCE ADX-1612, AN INVESTIGATIONAL NEW HSP90 INHIBITOR WITH POTENTIAL NANOMOLAR POTENCY AGAINST SARS-COV-2, TO CLINICAL TESTING FOR COVID-19; ADX-629 ACCEPTED FOR BARDA CORONAWATCH MEETING

BRIEF-Aldeyra Therapeutics Q1 Loss Per Share $0.34

* ALDEYRA THERAPEUTICS REPORTS FIRST-QUARTER 2020 FINANCIAL RESULTS AND ANNOUNCES NEW CLINICAL PROGRAMS

BRIEF-Aldeyra To Screen Clinical-Stage Compounds For Activity In COVID-19 Infection

* ALDEYRA TO SCREEN CLINICAL-STAGE COMPOUNDS FOR ACTIVITY IN COVID-19 INFECTION

BRIEF-Aldeyra Therapeutics Provides Updates On Anticipated Clinical Milestones

* ALDEYRA THERAPEUTICS REPORTS FULL-YEAR 2019 FINANCIAL RESULTS AND PROVIDES UPDATES ON ANTICIPATED CLINICAL MILESTONES

Aldeyra's eye drug meets main goal in late-stage study, shares surge

Aldeyra Therapeutics Inc said on Tuesday its drug reproxalap to treat a form of allergic reaction to the eye met the main goal in a late-stage trial, sending shares up more than 60 percent.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up